Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder March 22, 2021 • 2:30 PM EDT
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR March 19, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2 March 17, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights March 15, 2021 • 4:45 PM EDT
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia March 15, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences March 9, 2021 • 7:30 AM EST
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement March 4, 2021 • 7:00 AM EST
Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm) February 11, 2021 • 7:00 AM EST
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference February 10, 2021 • 7:00 AM EST
Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules February 9, 2021 • 4:05 PM EST
